Market Research Logo

Anti-obesity Drugs Market in the US 2015-2019

Anti-obesity Drugs Market in the US 2015-2019

About Obesity

Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.

Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Vendors

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novo Nordisk
  • Orexigen Therapeutics
  • Vivus
Other Prominent Vendors
  • Alizyme
  • Amylin
  • Boehringer Ingelheim
  • Eisai
  • Merck
  • Norgine
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Zafgan
Key Market Driver
  • Growing Prevalence Population
  • For a full, detailed list, view our report
Key Market Challenge
  • Serious Adverse Events and Multiple Drug Withdrawals
  • For a full, detailed list, view our report
Key Market Trend
  • Diversification of Investigational Pipeline
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Anti-obesity Drugs Market in the US 2015-2019

Technavio recognizes the following companies as the key players in the Anti-obesity Drugs Market in the US: Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics and Vivus

Other Prominent Vendors in the market are: Alizyme, Amylin, Boehringer Ingelheim, Eisai, Merck, Norgine, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical and Zafgan

Commenting on the report, an analyst from Technavio’s team said: “Many anti-obesity drugs have been issued complete response letters (CRLs) by the FDA before approval. For instance, the FDA issued a CRL to Takeda/Orexigen Therapeutics's Contrave in 2010, which requested further details regarding the cardiovascular safety profile of the drug when used over the long term in a population of overweight and obese subjects. Similarly, Vivus/Eisai's Qsymia was also issued a CRL, which requested further details regarding the clinical label, Risk Evaluation and Mitigation Strategy, safety update, and drug scheduling data. Thus, stringent regulations will hamper market growth.”

According to the report, Epidemiological statistics clearly signify that the target population for anti-obseity drugs is huge. In addition, advances in medical technologies have led to a rise in the number of people diagnosed with obesity. Thus the high number of overweight people coupled with improved diagnostics will drive the growth of the market.

Further, the report states that enormous R&D expenses coupled with high attrition rates pose a major challenge to the discovery and development of anti-obesity drugs.

Companies Mentioned

Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Vivus, Alizyme, Amylin, Boehringer Ingelheim, Eisai, Merck, Norgine, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Zafgan

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Xenical
    • Qsymia
    • Belviq
    • Saxenda
    • Contrave
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
      • Etiology and Comorbidities
        • Table Causes and Comorbidities of Obesity
      • Classification of Obesity
      • Epidemiology
        • Table Prevalence of Adults Overweight or Obese in US
        • Table Prevalence Rate of Children Overweight or Obese in US
      • Economic Burden Due to Obesity
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Anti-obesity Drugs Market in US 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Drug Class
    • Table Segmentation of Anti-obesity Drugs Market in US by Drug Class
    • Peripherally Acting Anti-obesity Drugs
    • Centrally Acting Anti-obesity Drugs
  • Market Segmentation by Medication Type
    • Table Segmentation of Anti-obesity Drugs Market in US by Medication Type
    • Monotherapies
    • Polytherapies
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and Their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Pipeline Snapshot
  • Trends and Their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • F. Hoffmann-La Roche
        • Table Key Takeaways: F. Hoffman-La Roche
      • GlaxoSmithKline
        • Table Key Takeaways: GlaxoSmithKline
      • Vivus
        • Table Key Takeaways: Vivus
      • Arena Pharmaceuticals
        • Table Key Takeaways: Arena Pharmaceuticals
      • Orexigen Therapeutics
        • Table Key Takeaways: Orexigen
      • Novo Nordisk
        • Table Key Takeaways: Novo Nordisk
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Arena Pharmaceuticals
      • Key Facts
      • Business Overview
      • Geographical Segmentation
        • Table Arena Pharmaceuticals: Geographical Segmentation
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
      • Geographical Segmentation by Revenue
        • Table F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
        • Table F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billions)
      • Sales by Geography
        • Table GlaxoSmithKline: Sales by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Orexigen Therapeutics
      • Key Facts
      • Business Overview
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Vivus
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Vivus: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Vivus: Business Segmentation by Revenue 2012 and 2013 ($ millions)
      • Geographical Segmentation by Revenue 2013
        • Table Vivus: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Information
      • SWOT Analysis
    • Novo Nordisk
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Novo Nordisk: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
      • Sales by Geography
        • Table Novo Nordisk: Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
  • Other Reports in This Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report